|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 263.92 USD | -1.60% |
|
-1.58% | -13.13% |
| 12/06 | BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses | MT |
| 12/06 | BeOne Medicines Announces New Data From Foundational Hematology Franchise At EHA 2026 | CI |
Company Valuation: BeOne Medicines AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 27,843 | 22,843 | 18,862 | 19,667 | 33,619 | 29,341 | - | - |
| Change | - | -17.96% | -17.43% | 4.27% | 70.94% | -12.72% | - | - |
| Enterprise Value (EV) 1 | 24,097 | 19,511 | 16,564 | 18,058 | 30,091 | 25,281 | 24,359 | 22,515 |
| Change | - | -19.03% | -15.1% | 9.02% | 66.64% | -15.98% | -3.65% | -7.57% |
| P/E Ratio | -17.8x | -11.3x | -21.3x | -30.2x | 120x | 39.4x | 27.3x | 20.3x |
| PBR | 4.03x | 5.17x | 5.32x | 5.84x | 7.9x | 5.87x | 4.64x | 3.24x |
| PEG | - | -0.4x | 0.4x | 1.1x | -1x | 0x | 0.6x | 0.6x |
| Capitalization / Revenue | 23.7x | 16.1x | 7.67x | 5.16x | 6.29x | 4.53x | 3.95x | 3.51x |
| EV / Revenue | 20.5x | 13.8x | 6.74x | 4.74x | 5.63x | 3.9x | 3.28x | 2.69x |
| EV / EBITDA | -17.3x | -11.3x | -14.8x | -45.6x | 51.1x | 25x | 16.8x | 10.4x |
| EV / EBIT | -16.7x | -10.9x | -13.7x | -31.8x | 67.3x | 29.6x | 20x | 12.8x |
| EV / FCF | -15.4x | -10.7x | -9.63x | -28.5x | 32x | 36.7x | 22.3x | 14.8x |
| FCF Yield | -6.48% | -9.34% | -10.4% | -3.51% | 3.13% | 2.73% | 4.48% | 6.75% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -15.23 | -19.43 | -8.45 | -6.12 | 2.53 | 6.703 | 9.662 | 13 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,176 | 1,416 | 2,459 | 3,810 | 5,343 | 6,479 | 7,435 | 8,357 |
| EBITDA 1 | -1,392 | -1,723 | -1,120 | -396.4 | 588.8 | 1,012 | 1,447 | 2,167 |
| EBIT 1 | -1,439 | -1,790 | -1,208 | -568.2 | 447.1 | 854.7 | 1,220 | 1,761 |
| Net income 1 | -1,413 | -2,004 | -881.7 | -644.8 | 286.9 | 762.6 | 1,100 | 1,540 |
| Net Debt 1 | -3,746 | -3,332 | -2,297 | -1,609 | -3,528 | -4,060 | -4,982 | -6,826 |
| Reference price 2 | 270.93 | 219.94 | 180.36 | 184.71 | 303.81 | 263.92 | 263.92 | 263.92 |
| Nbr of stocks (in thousands) | 102,770 | 103,859 | 104,578 | 106,476 | 110,658 | 111,174 | - | - |
| Announcement Date | 25/2/22 | 27/2/23 | 26/2/24 | 27/2/25 | 26/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 39.37x | 3.9x | 24.99x | -.--% | 29.34B | |
| 29.85x | 5.29x | 16.41x | 1.1% | 43.51B | |
| -19.69x | 291.06x | -17.93x | -.--% | 33.29B | |
| 21.8x | 2.52x | 10.89x | -.--% | 29.9B | |
| 29.49x | 7.59x | 19.52x | 0.4% | 25.42B | |
| 27.09x | 4.34x | 19.75x | -.--% | 13.18B | |
| 21.78x | 1.9x | 8.34x | 1.22% | 12.72B | |
| -20.24x | 13.32x | -19.83x | -.--% | 12.08B | |
| 22.84x | 1.66x | 10.02x | -.--% | 10.99B | |
| Average | 16.92x | 36.84x | 8.02x | 0.3% | 23.38B | |
| Weighted average by Cap. | 18.25x | 50.19x | 9.07x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ONC Stock
- Valuation BeOne Medicines AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition